Abstract:1083 Introduction: High kidney uptake is a common feature of radiolabeled peptides, and this reduces detection sensitivity for lesions adjacent to kidneys and lowers maximum tolerated dose for radiotherapeutic application. The Met-Val-Lys (MVK) linker has been shown to reduce kidney uptake of 68Ga-labeled NOTA-conjugated peptides. The resulting lower kidney uptake was attributed to recognition and cleavage of the MVK sequence between MV by neprilysin (NEP), an endopeptidase found in abundance on the renal brush border lining. However, the use of NOTA chelator excludes application of such peptides for therapy using radioisotopes like 177Lu. For potential theranostic applications, DOTA is the preferred radiometal chelator. In this study, we evaluated if the MVK linker could be used to lower the kidney uptake of 68Ga-labeled DOTA-conjugated peptides as well. Methods: The DOTA conjugated linker (DOTA-AmBz-MVK(Ac)-OH; AmBz: 4-aminomethylbenzoyl), the expected cleaved metabolite DOTA-AmBz-Met-OH, and a PSMA-targeting ligand DOTA-AmBz-MVK(HTK01166)-OH were synthesized on solid-phase using standard Fmoc chemistry. All peptides were cleaved from resin with trifluoroacetic acid and purified by HPLC. Complexation with nonradioactive Ga and 68Ga was conducted in acetate (pH 4.5) and HEPES (pH 5.0) buffer, respectively. Renal proximal tubular brush-border membrane vesicles (BBMVs) were extracted from mouse kidneys. For NEP enzymatic recognition assay, Ga-68 labeled peptides were incubated with BBMVs (at 37 °C, 1 h) with/without the NEP inhibitor phosphoramidon (1 mg/well), and monitored by HPLC. In vivo stability was conducted in male NSG mice and the radiometabolites in blood (at 5 min post-injection, p.i.) and urine (15 min p.i.) were monitored by HPLC. PET/CT imaging and biodistribution studies were performed in mice bearing LnCap prostate cancer xenografts. Results: The DOTA-conjugated peptides and their Ga-complexes were successfully synthesized, and their identities were confirmed by MS analysis. Both in vitro and in vivo assays revealed complete cleavage (> 99%) of 68Ga-DOTA-AmBz-MVK(Ac)-OH with the expected 68Ga-DOTA-AmBz-Met-OH as the dominate radiometabolite (> 90%). The cleavage of 68Ga-DOTA-AmBz-MVK(Ac)-OH was inhibited (metabolite < 15%) in the presence of phosphoramidon in the in vitro enzyme assay. In vivo study showed that 68Ga-DOTA-AmBz-Met-OH was fast excreted from the body exclusively via the renal pathway with minimal kidney retention (<2.5 %ID/g). As for the PSMA-targeting ligand 68Ga-DOTA-AmBz-MVK(HTK01166)-OH, it was cleaved less effectively (79.6% intact) in the in vitro assay. The in vivo stability study also showed intact 68Ga-DOTA-AmBz-MVK(HTK01166)-OH (9%), the expected fragment 68Ga-DOTA-AmBz-Met-OH as a minor metabolite (35%) and an unidentified major radiometabolite (56%) in the blood. In the urine samples, only 68Ga-DOTA-AmBz-Met-OH (80%) and the intact tracer (20%) were detected. Imaging and biodistribution revealed lower tumor (3.98 %ID/g) and kidney (104 %ID/g) of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH when compared to those of previously reported PSMA-targeting 68Ga-HTK01166 (14.1 and 147 %ID/g, respectively). Conclusions: We demonstrated that MVK can be inserted between DOTA and the targeting peptide sequences, and the resulting 68Ga-labeled peptides can be cleaved specifically between M-V by NEP. Due to very low kidney retention of the expected fragment, this strategy can be used to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides, and potentially their 177Lu-labeled analogs for radiotherapy. High renal uptake of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH could be due to renal retention of the unknown metabolite. This underscores the importance of conducting a thorough structure-activity-relationship study when applying this strategy to reduce kidney uptake of radiopeptides.

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs

Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Influence of different spacers on the biological profile of a DOTA-somatostatin analogue

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis

Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer

P066 Transmission Ofneisseria Gonorrhoeaeamong Men Who Have Sex with Men: an Anatomical Site-Specific Mathematical Model and Impact of Mouthwash

Synthesis and Evaluation of Met-Val-Lys As a Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-conjugated Peptides

Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles

Radiolabelled CCK2 R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation

First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody

Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity

Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor

Prolonged Activation of the GLP-1 Receptor via Covalent Capture

Examination of Charge Modifications of an Endolysosomal Trapping Inhibitor in an Antagonistic NTSR1-Targeted Construct for Colon Cancer

Combination of the amide-to-triazole substitution strategy with alternative structural modifications for the metabolic stabilization of tumor-targeting, radiolabeled peptides